Cancer waiting times aren’t just a performance metric. They’re an access problem. And they’re a survival problem.

Two headlines landed within days of each other this week:

  • Cancer Research UK: “Cancer waiting times: Latest updates and analysis”

  • The Independent: “Mapped: English areas with the NHS worst cancer referral treatment times revealed”

Together, they tell an uncomfortable truth: we’re getting faster at diagnosis… but we’re still too slow at starting treatment. And that gap is where patients lose options.

The latest national picture looks “OK” until you look at the bit that matters most

Cancer Research UK’s breakdown of NHS England data for December 2025 shows:

  • Faster Diagnosis Standard (28 days): 77.4% (target 75%) — target met.

  • 62-day referral-to-treatment: 71.9% (target 85%) — target missed.

  • 31-day decision-to-treat: 92.5% (target 96%) — target missed.

Put simply, England is meeting the “find out” standard, but missing the “start treatment” standards.

And yes, the standards were streamlined into these three core measures from October 2023 (so we’re not comparing like-for-like with older reporting).

The trust-by-trust map shows something even harder to defend: huge variation

The Independent’s analysis (using NHS England figures, with support from Cancer Research UK) makes the variation impossible to ignore.

A few data points that should stop us scrolling:

  • In 2025, only 3 of 119 acute trusts with comparable data hit the 85% 62-day standard, while the worst was at 45.4% (Mid & South Essex).

  • The article reports that an interim ambition of 75% by March 2026 was only achieved by 33 of 119 trusts in 2025.

  • And in December 2025, in some trusts, around one in seven (or more) of patients starting treatment had already waited over 104 days since urgent referral, rising to ~17% in Mid & South Essex and 16.5% in Hull University Teaching Hospitals.

This is the part we don’t say loudly enough:

When performance ranges from “almost 9 in 10 treated on time” to “less than half treated on time”, you don’t have a national standard. You have a postcode lottery.

Delays don’t just create anxiety — they change outcomes

Cancer Research UK makes the point we all know instinctively: earlier diagnosis and treatment improve the chance of successful treatment.

The harder part is quantifying harm. But we do have evidence that time matters:

A major BMJ systematic review and meta-analysis estimated that a 4‑week delay to cancer surgery is associated with a 6–8% higher risk of death (with impacts also seen across systemic therapy and radiotherapy, varying by indication).

So, when parts of the system are seeing people waiting 104+ days from urgent referral to starting treatment, it’s not just “missing a target”. It’s accumulating clinical risk.

And there’s a brutal feedback loop here:

  • delayed treatment → more advanced disease

  • more advanced disease → more complex (and expensive) treatment

  • more complex treatment → more pressure on capacity

  • more pressure → longer waits

The system gets sicker while trying to treat sickness.

The downstream impact that isn’t being talked about enough: NICE TA becomes “paper access”

Here’s the uncomfortable bridge between cancer waiting times and innovation access.

NICE Technology Appraisals (TAs) exist so that effective, cost-effective treatments can reach patients. And the system has rules to make that real:

  • NICE states commissioners have a statutory responsibility to fund treatments recommended by a NICE TA/HST no later than 90 calendar days after guidance is published (unless otherwise specified).

  • NICE is explicit about what “compliance” actually means: a patient and clinician should be able to choose a NICE‑recommended option without local funding or formulary restrictions.

But here’s the problem:

A 90‑day funding mandate doesn’t automatically equal 90‑day patient access — if the pathway can’t deliver the basics of diagnosis, staging, MDT decisions, and treatment start on time.

Now add modern oncology reality:

  • more TAs

  • more biomarker-driven indications

  • more companion diagnostics and genomic testing

  • more pathway steps before the “right” patient can receive the “right” treatment

The Independent notes the government plan aims to increase access to things like genomic testing, but that is only meaningful if the pathway can absorb it and our experience suggests that the genomic testing pathway is subject to the same variation issues as the cancer standards.

So what happens downstream when waits are long and variable?

1) Patients miss the window

Even when a TA exists, delays can push patients to later stage, poorer fitness, or different lines of therapy, meaning they may no longer meet the criteria or are less likely to benefit.

2) Real-world uptake lags behind “funding compliance”

Organisations can be technically compliant on paper (funding available), while access in practice is inconsistent because diagnostics and clinic capacity are the limiting factor.

3) Inequality gets baked in

If Trust A runs at ~89% on the 62-day metric and Trust B runs at ~45%, then the same NICE TA will land very differently depending on where you live.

4) Value gets diluted

NICE decisions assume pathways that can deliver treatment in a clinically meaningful timeframe. If the system delivers later, the health gain we’re paying for may simply not materialise in full (and that should worry all of us who talk about value-based healthcare).

So what do we do next? Three practical shifts that make “access” real

This isn’t about blaming frontline teams. The CRUK analysis is clear: staff are working under intense pressure, and progress needs funding, oversight, governance, and delivery structures that actually work.

If we’re serious about patient outcomes and about innovation, three changes feel non-negotiable:

1) Treat the 62-day standard as an end-to-end pathway problem (not a single KPI)

If you can hit 28 days but miss 62 days, the bottleneck is after suspicion/diagnosis, in staging, MDT capacity, theatre slots, radiotherapy capacity, systemic treatment delivery, pharmacy, workforce, and scheduling. Fixing that requires pathway ownership, not just performance management.

2) Stop accepting variation as “local context”

When one trust is at ~89% and another is at ~45%, that is not nuance — it’s inequity. We need transparency, shared learning, and support that moves lagging systems faster.

3) Make TA implementation operational, not theoretical

A TA landing should trigger a repeatable playbook: diagnostics readiness, MDT decision points, formulary steps, patient information, booking capacity, and tracking real-world uptake. The NICE 90‑day requirement is a forcing function — but only if we treat it as a delivery discipline, not a legal footnote.

If we normalise long waits for cancer treatment, we are choosing worse outcomes, and we are quietly undermining every NICE TA that’s supposed to improve survival and quality of life.

We can celebrate hitting the Faster Diagnosis Standard. We should.

But we can’t pretend that a timely diagnosis equals timely care.

Because when it comes to cancer:

access delayed is access denied — and sometimes it’s survival denied.

If you’re working in cancer services, commissioning, med tech, pharma, diagnostics, or policy: where do you think the biggest “fixable” bottleneck sits right now, diagnostics, MDT capacity, treatment delivery, or pathway coordination?